等待开盘 05-12 09:30:00 美东时间
+0.050
+0.11%
Madrigal Pharmaceuticals to Present at the 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025. The presentation will be webcast live and available for replay. Madrigal focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with Rezdiffra, its FDA-approved medication for MASH with moderate to advanced fibrosis. For more information, visit Madrigal’s Investor Relations page.
2025-06-02 12:00